IMRX Stock Analysis: Buy, Sell, or Hold?
IMRX - Immuneering Corporation Class A Common Stock
$5.30
0.05 (0.95%)
▲
5d:
+4.74%
30d:
+20.73%
90d:
+1.53%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When IMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IMRX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IMRX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMRX is currently trading at $5.30, which is considered extended relative to its 30-day fair value range of $4.24 to $5.03.
Technical Outlook: Technically, IMRX is in a strong uptrend. The price is approaching resistance at $5.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.25 (+244.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMRX is in a strong uptrend. The price is approaching resistance at $5.43. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: IMRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.25 (+244.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.24 -
$5.03
Company Quality Score
39/100
(SELL)
Options IV Signal
36th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
31.2%
All Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- NEUTRAL: Options fairly priced (IV 36th percentile)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 244.3% below Wall St target ($18.25)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.24 -
$5.03
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.69
(13.0%)
Support & Resistance Levels
Support Level
$4.51
Resistance Level
$5.43
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.17
Wall Street Target
$18.25
(+244.3%)
Revenue Growth (YoY)
-99.8%
Share & Embed Analysis
Last updated: August 24, 2026 2:19 AM ET
Data refreshes hourly during market hours. Next update: 3:19 AM
Data refreshes hourly during market hours. Next update: 3:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
